Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Regencell Bioscience Holdings Ltd
Research & Development
Regencell Bioscience Holdings Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Research & Development
-$948.3k
|
CAGR 3-Years
28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Research & Development
-¥921m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-31%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Research & Development
-¥5.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Research & Development
-HK$2.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Research & Development
-$148.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-12%
|
|
Regencell Bioscience Holdings Ltd
Glance View
Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 13 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
See Also
What is Regencell Bioscience Holdings Ltd's Research & Development?
Research & Development
-948.3k
USD
Based on the financial report for Jun 30, 2025, Regencell Bioscience Holdings Ltd's Research & Development amounts to -948.3k USD.
What is Regencell Bioscience Holdings Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-19%
Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for Regencell Bioscience Holdings Ltd have been 28% over the past three years , -19% over the past five years .
